Free Trial
Want deep insights into your competitors & competitive landscape? Try Patsnap Eureka!

Top 20 Key Players companies in Imipenem
by Highest Patent Value in the China in 2022

The Imipenem top 20 is Discovery PatSnap’ annual ranking of the top 20 Highest Patent Value Imipenem Key Players in the China. Discovery has identified the top key players, startups & unicorns, fast-growings, news entrants in 2022, ranking from differnt perspectives, including patent filing intensity, academic research capability, news media heat. The company list is generated from various data types.
Imipenem (Primaxin among others) is an intravenous β-lactam antibiotic discovered by Merck scientists Burton Christensen, William Leanza, and Kenneth Wildonger in the mid-1970s. Carbapenems are highly resistant to the β-lactamase enzymes produced by many multiple drug-resistant Gram-negative bacteria, thus play a key role in the treatment of infections not readily treated with other antibiotics.
#
Company Name
Region
Tech Topics
Total
1
Asymchem Laboratories (Tianjin) Co., Ltd.
Avg patent value: 3.20 M
2
Contract Manufacturing
Avg patent value: 3.20 M
3
Avg patent value: 3.20 M
4
Avg patent value: 100,000
5
Avg patent value: 100,000
6
Avg patent value: 99,000
7
Avg patent value: 68,000
8
Avg patent value: 66,000
9
Avg patent value: 63,333
10
Medicine,Health care,Excipient,
...[+2]
Avg patent value: 63,000
11
Avg patent value: 47,000
12
Avg patent value: 40,000
13
Avg patent value: 39,000
14
Drug,Health care,Buspirone,
...[+2]
Avg patent value: 23,000
15
Avg patent value: 23,000
16
Health care,Research system,International health,
...[+2]
Avg patent value: 23,000
17
Avg patent value: 3,500
18
Avg patent value: 3,400
19
Health care,Drugs production,Drug,
...[+2]
Avg patent value: 0
20
Avg patent value: 0
Page generation time: Apr 27 2025